StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen r&d expenses

Research and development expenses are spending on new products and technology.

Biogen's R&D Expenses for the twelve months ending Sep 30, 2026 was $2.15B, up 20.7% year over year. For fiscal 2025 it was $1.78B, down 10.2% from the year before. Over ten years it grew -1.2% a year on average. The highest annual figure on record is $3.99B in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.78B-10.2%
FY2024Dec 31, 2024$1.98B-19.0%
FY2023Dec 31, 2023$2.45B+9.6%
FY2022Dec 31, 2022$2.23B-10.8%
FY2021Dec 31, 2021$2.50B-37.3%
FY2020Dec 31, 2020$3.99B+75.0%
FY2019Dec 31, 2019$2.28B-12.2%
FY2018Dec 31, 2018$2.60B+15.2%
FY2017Dec 31, 2017$2.25B+14.2%
FY2016Dec 31, 2016$1.97B-2.0%
FY2015Dec 31, 2015$2.01B+6.3%
FY2014Dec 31, 2014$1.89B+31.1%
FY2013Dec 31, 2013$1.44B+8.2%
FY2012Dec 31, 2012$1.33B+9.5%
FY2011Dec 31, 2011$1.22B-2.3%
FY2010Dec 31, 2010$1.25B-2.7%
FY2009Dec 31, 2009$1.28B+19.7%
FY2008Dec 31, 2008$1.07B+15.9%
FY2007Dec 31, 2007$925.16M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$574.00M+31.6%
Q2 FY2026Jun 30, 2026$529.60M+32.7%
Q1 FY2026Mar 31, 2026$539.00M+24.2%
Q4 FY2025Dec 31, 2025$509.40M-0.8%
Q3 FY2025Sep 30, 2025$436.10M-15.5%
Q2 FY2025Jun 30, 2025$399.00M-21.1%
Q1 FY2025Mar 31, 2025$434.10M-2.5%
Q4 FY2024Dec 31, 2024$513.30M-7.4%
Q3 FY2024Sep 30, 2024$516.20M-29.9%
Q2 FY2024Jun 30, 2024$505.40M-13.5%
Q1 FY2024Mar 31, 2024$445.40M-21.9%
Q4 FY2023Dec 31, 2023$554.30M-7.9%
Q3 FY2023Sep 30, 2023$736.30M+34.1%
Q2 FY2023Jun 30, 2023$584.20M+10.5%
Q1 FY2023Mar 31, 2023$570.60M+3.4%
Q4 FY2022Dec 31, 2022$601.60M-14.0%
Q3 FY2022Sep 30, 2022$549.20M-21.8%
Q2 FY2022Jun 30, 2022$528.60M-9.7%
Q1 FY2022Mar 31, 2022$551.70M+7.3%
Q4 FY2021Dec 31, 2021$699.50M-59.5%
Q3 FY2021Sep 30, 2021$702.40M-38.4%
Q2 FY2021Jun 30, 2021$585.10M-9.7%
Q1 FY2021Mar 31, 2021$514.20M+8.0%
Q4 FY2020Dec 31, 2020$1.73B+149.5%
Q3 FY2020Sep 30, 2020$1.14B+111.1%
Q2 FY2020Jun 30, 2020$647.60M+33.6%
Q1 FY2020Mar 31, 2020$476.30M-15.5%
Q4 FY2019Dec 31, 2019$691.70M+13.1%
Q3 FY2019Sep 30, 2019$540.40M+6.4%
Q2 FY2019Jun 30, 2019$484.80M-50.6%
Q1 FY2019Mar 31, 2019$563.70M+13.5%
Q4 FY2018Dec 31, 2018$611.60M+4.1%
Q3 FY2018Sep 30, 2018$507.90M+13.8%
Q2 FY2018Jun 30, 2018$981.00M+23.2%
Q1 FY2018Mar 31, 2018$496.70M+17.3%
Q4 FY2017Dec 31, 2017$587.60M+10.1%
Q3 FY2017Sep 30, 2017$446.40M–
Q2 FY2017Jun 30, 2017$796.20M–
Q1 FY2017Mar 31, 2017$423.40M–
Q4 FY2016Dec 31, 2016$533.90M–

More Biogen figures

See a number that looks wrong?